塞利尼索治疗复发难治性多发性骨髓瘤的研究进展
Research progress of selinexor in the treatment of recurrent and refractory multiple myeloma
刘恒 1吴涛1
作者信息
- 1. 中国人民解放军联勤保障部队第九四○医院血液科/全军血液病中心,兰州 730050
- 折叠
摘要
多发性骨髓瘤是一种不可治愈的血液系统恶性肿瘤,尽管近年来蛋白酶体抑制剂、免疫调节剂等治疗药物及嵌合抗原受体T细胞(CAR-T)疗法的不断发展改善了预后,但仍有部分患者耐药,表现为难治、复发,治疗选择有限.塞利尼索是一种首创、口服的选择性核输出蛋白抑制剂,通过结合并抑制核输出蛋白1发挥作用,导致肿瘤抑制蛋白在细胞核内累积,癌细胞选择性凋亡,在复发难治性多发性骨髓瘤中显示出可控的毒性和良好的疗效.本文就塞利尼索的抗肿瘤机制、临床研究进展以及不良反应等进行讨论.
Abstract
Multiple myeloma is an incurable hematological malignancy.Although the continuous development of therapeutic drugs such as proteasome inhibitors and immune modulators,as well as chimeric antigen receptor T-cell(CAR-T)therapy,has improved the prognosis in recent years,some patients are still drug-resistant,presenting as refractory and recurrent disease with limited treatment options.Selinexor,a first-in-class oral selective nuclear export protein inhibitor,binds to and inhibits nuclear export protein XPO-1 to function,leading to the accumulation of tumor suppressor proteins in the nucleus and selective apoptosis of cancer cells.It has shown controllable toxicity and good efficacy in the treatment of recurrent and refractory multiple myeloma.This article discusses the anti-tumor mechanism of selinexor,its clinical research progress,and adverse reactions.
关键词
多发性骨髓瘤/塞利尼索/核输出蛋白1Key words
Multiple myeloma/Selinexor/Exportin 1引用本文复制引用
基金项目
甘肃省临床医学研究中心建设项目(21JR7RA015)
出版年
2024
NETL
NSTL
万方数据